---
title: "Drug Approval and Manufacturing in Israel"
description: "Israel’s Health Ministry enforces good manufacturing practice requirements and inspects medicine production sites. FDA records document inspections at Teva’s Kfar Saba facility; an inspection evaluates a site, while product approval applies to a specific drug."
url: "https://hasbara.co.il/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/fda-approval-of-kfar-saba-and-israeli-drug-exports"
type: "resource-page"
locale: "en"
categories: ["Israeli Pharmaceutical Industry: Teva and Generic Drugs"]
---

# Drug Approval and Manufacturing in Israel

*Israel’s Health Ministry enforces good manufacturing practice requirements and inspects medicine production sites. FDA records document inspections at Teva’s Kfar Saba facility; an inspection evaluates a site, while product approval applies to a specific drug.*

Israel’s Ministry of Health oversees good manufacturing practice (GMP) at sites that make and handle medicines and active ingredients. The U.S. FDA separately inspects facilities supplying the American market and reviews individual medicines for approval. Teva’s Kfar Saba facility appears in FDA inspection records, which describe site inspections rather than a blanket approval for every drug made there.

## Israel inspects manufacturing quality

The Ministry of Health’s GMP inspectorate enforces Israeli pharmaceutical manufacturing rules. Its inspections cover facilities and operations involved in manufacturing, packaging, storing, testing, importing and exporting medicines, as well as active ingredients. The inspectorate can issue GMP certificates and take enforcement action when a site fails to meet requirements. The ministry explains these duties on its [pharmaceutical standards and quality-control page](https://www.gov.il/he/Departments/units/pharmaceutical-standards-and-quality-control).

Manufacturing oversight and a medicine’s marketing authorization address different questions. An inspection assesses whether a site’s systems and processes meet applicable standards. A product review evaluates a particular medicine, its quality, safety and efficacy for a proposed use. A facility inspection alone does not authorize every product manufactured there for sale.

## What FDA records say about Kfar Saba

Teva’s own history labels a Kfar Saba facility event in 1982 as an FDA approval milestone. FDA regulatory files use more precise terms for later interactions. A 2012 FDA review of a biologics application records a GMP and pre-approval inspection at Teva Pharmaceutical Industries in Kfar Saba; the review says the inspection was classified VAI, meaning Voluntary Action Indicated, for the cited areas. The [FDA microbiology review](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125294Orig1s000MicroR.pdf) documents the site inspection and classification.

The site inspection record belongs to the facility’s compliance history. It is distinct from FDA approval of a specific drug application. Teva’s [company timeline](https://www.tevapharm.com/our-company/teva-history/) provides the 1982 milestone wording, while FDA records show how facility inspections are described in regulatory documents. Teva’s expansion in the U.S. generics market is covered in [the account of its international growth](https://hasbara.co.il/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/eli-hurvitz-and-the-globalization-of-teva-pharmaceuticals).

## Pages

- [From S.L.E. to Teva: The Industry's Early History](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-early-history-and-consolidation-of-teva-pharmaceuticals.md)
- [Eli Hurvitz and Teva's Global Expansion](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/eli-hurvitz-and-the-globalization-of-teva-pharmaceuticals.md)
- [Teva's API Business and the Global Drug Supply](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/teva-active-pharmaceutical-ingredients-and-the-global-drug-supply.md)
- [Copaxone: Weizmann Research to Multiple Sclerosis Treatment](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-breakthrough-development-and-global-success-of-copaxone.md)
- [Azilect: Technion Research and Clinical Development](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/the-clinical-development-of-azilect.md)
- [Israeli Pharmaceutical Research, Manufacturing and Exports](/resources/israeli-pharmaceutical-industry-teva-and-generic-drugs/academic-industrial-collaboration-in-israeli-drug-discovery.md)

## Sources

- [gov.il](https://www.gov.il/he/Departments/units/pharmaceutical-standards-and-quality-control)
- [accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125294Orig1s000MicroR.pdf)
- [tevapharm.com](https://www.tevapharm.com/our-company/teva-history/)
